EGFRvIII Targeted Chimeric Antigen Receptor CAR-T Cell Therapy (Chembrain)

N/A

Report date: 2024/11/26 20:00:06

Base Information

Drug NameEGFRvIII Targeted Chimeric Antigen Receptor CAR-T Cell Therapy (Chembrain)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements

TargetsEpidermal growth factor receptor variant III

Therapy Area/IndicationsGlioblastomaGlioma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFinlandIndia

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesChembrain Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesChembrain Ltd

Active IndicationsN/A

Inactive IndicationsGlioblastomaGlioma

Other Information

ATC CodeN/A